Research Topics
| Vahakn B ShahinianSummaryAffiliation: University of Texas Medical Branch Country: USA Publications
| Collaborators
|
Detail Information
Publications
Risk of fracture after androgen deprivation for prostate cancerVahakn B Shahinian
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
N Engl J Med 352:154-64. 2005..This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied...- Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinomaVahakn B Shahinian
Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 0562, USA
Cancer 103:1615-24. 2005..The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, in population-based tumor registries... 
Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancerVahakn B Shahinian
Department of Internal Medicine, and Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
Arch Intern Med 166:465-71. 2006..We therefore sought to estimate the incidence of these effects and, by using a control group, ascertain whether these effects were related to androgen deprivation itself...- Determinants of androgen deprivation therapy use for prostate cancer: role of the urologistVahakn B Shahinian
Department of Internal Medicine, University of Texas Medical Branch, John Sealy Annex 4 200, 301 University Blvd, Galveston, TX 77555 0562, USA
J Natl Cancer Inst 98:839-45. 2006.... - Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancerVahakn B Shahinian
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0725, USA
J Clin Oncol 25:5359-65. 2007..Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we examined how individual urologist characteristics influenced the use of androgen deprivation therapy... 
Reimbursement policy and androgen-deprivation therapy for prostate cancerVahakn B Shahinian
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0725, USA
N Engl J Med 363:1822-32. 2010..We hypothesized that these reductions would lead to decreases in the use of ADT for indications that were not evidence based...- Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancerYong Fang Kuo
Department of Internal Medicine, Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX 77555 0177, USA
Med Care 50:374-80. 2012..We explored the potential advantages of using an instrumental variable approach in the context of primary androgen deprivation therapy (ADT) for prostate cancer... - Cause of death in older men after the diagnosis of prostate cancerMelanie Ketchandji
University of Texas Medical Branch, Galveston, Texas, USA
J Am Geriatr Soc 57:24-30. 2009..To compare survival and cause of death in men aged 65 and older diagnosed with prostate cancer and with survival and cause of death in a noncancer control population... - Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancerYong Fang Kuo
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
BMC Health Serv Res 8:146. 2008..We hypothesized that some men receive these agents after only a limited work-up for their cancer. Such cases may be missed by tumor registries, leading to underestimates of the total extent of GnRH agonist use... - Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general populationShilpa Taneja
Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
Clin J Am Soc Nephrol 2:1008-13. 2007..It is therefore unclear whether dialysis patients are disadvantaged in terms of cancer diagnosis. This study compared stage at diagnosis of cancer in a population-based sample of patients with ESRD versus the general population... - Risk of malignancy with long-term immunosuppression in renal transplant recipientsMahendra L Agraharkar
Division of Nephrology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
Kidney Int 66:383-9. 2004..Available data pertaining to cancer risks in renal transplant recipients have been inconsistent, and much of it is derived from international studies, which may not be truly representative of the United States population... - Are chronic dialysis patients at increased risk for cancer?Sreedhar Mandayam
Wichita Nephrology Group, Wichita, KS, USA
J Nephrol 21:166-74. 2008..Further research is needed before routine screening for bladder or renal cell cancers can be recommended... - Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipientsVahakn B Shahinian
Multi-Organ Transplant Unit, London Health Sciences Center, University of Western Ontario, London, Ontario, Canada
Transplantation 75:851-6. 2003..These results indicate that primary infection with EBV may have a pathogenic role in some cases of late PTLD...